Lonza has launched Capsugel Zephyr, a new dry-powder inhalation (DPI) capsule portfolio for customized solutions for optimal pulmonary drug delivery. Lonza’s Capsule Delivery Solutions developed Capsugel Zephyr capsules as a portfolio of high-quality, highly customizable DPI capsules of different polymers and compositions, and product customization services to help address the specific needs of inhalation drug products manufacturers.
“Capsule-based DPI technology is quickly becoming the preferred DPI drug delivery platform for pulmonary delivery. It provides drug stability advantages, encourages patient compliance and is cost-effective to manufacture with various dose carrying capacity. With more than 20 years of experience in manufacturing DPI- capsules, Lonza offers a uniquely customized portfolio of polymers to meet the growing need of inhalation DPI products for pulmonary drug delivery,” said Stef Vanquickenborne, vice president R&D, Lonza Pharma & Biotech.
The Capsugel Zephyr capsule portfolio aims to address comprehensive inhalation solutions that ensure end-product efficacy with consistent and optimal release performance regardless of formulation characteristics or DPI device principles. Lonza offers a full-service inhalation drug-delivery approach based on its particle engineering platforms, specialized encapsulation technologies as well as customized capsules for use with a large range of DPI devices. The portfolio is supported by a global integrated supply chain, quality and regulatory support and Lonza’s manufacturing network for associated services.
